Ikena Oncology (IKNA) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free IKNA Stock Alerts $1.40 -0.03 (-2.10%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17, 2024 | marketbeat.comShort Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Rises By 9.4%Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,520,000 shares, a growth of 9.4% from the April 15th total of 1,390,000 shares. Based on an average daily volume of 388,400 shares, the short-interest ratio is currently 3.9 days. Approximately 6.0% of the company's stock are sold short.May 17, 2024 | americanbankingnews.comIkena Oncology, Inc. (NASDAQ:IKNA) to Post Q2 2024 Earnings of ($0.26) Per Share, Wedbush ForecastsMay 17, 2024 | americanbankingnews.comWilliam Blair Equities Analysts Increase Earnings Estimates for Ikena Oncology, Inc. (NASDAQ:IKNA)May 16, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Forecasted to Earn Q2 2024 Earnings of ($0.26) Per ShareIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Wedbush raised their Q2 2024 EPS estimates for Ikena Oncology in a report released on Monday, May 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their previousMay 16, 2024 | americanbankingnews.comIkena Oncology (NASDAQ:IKNA) Stock Rating Reaffirmed by WedbushMay 14, 2024 | marketbeat.comIkena Oncology (NASDAQ:IKNA) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and set a $8.00 price objective on shares of Ikena Oncology in a research report on Tuesday.May 13, 2024 | investorplace.comIKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024May 13, 2024 | globenewswire.comIkena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateMay 1, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Short Interest Up 11.2% in AprilIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,390,000 shares, an increase of 11.2% from the March 31st total of 1,250,000 shares. Approximately 5.5% of the shares of the stock are sold short. Based on an average trading volume of 424,100 shares, the short-interest ratio is currently 3.3 days.April 21, 2024 | finance.yahoo.comIkena Oncology, Inc. (IKNA)April 10, 2024 | globenewswire.comIkena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 2, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Sees Large Growth in Short InterestIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 1,120,000 shares, a growth of 15.0% from the February 29th total of 974,000 shares. Approximately 4.5% of the company's shares are sold short. Based on an average daily trading volume, of 388,000 shares, the days-to-cover ratio is currently 2.9 days.March 19, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Ikena OncologyMarch 19, 2024 | marketbeat.comIkena Oncology (NASDAQ:IKNA) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $11.00 price target on shares of Ikena Oncology in a research note on Tuesday.March 16, 2024 | marketbeat.comShort Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Rises By 47.0%Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 974,000 shares, a growth of 47.0% from the February 14th total of 662,400 shares. Approximately 3.9% of the company's stock are short sold. Based on an average daily volume of 349,300 shares, the days-to-cover ratio is currently 2.8 days.March 14, 2024 | finance.yahoo.comIkena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 14, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Expected to Post FY2028 Earnings of ($0.36) Per ShareIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Stock analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of Ikena Oncology in a research report issued on Tuesday, March 12th. HC Wainwright analyst A. Maldonado forecasts that the company will post earninMarch 13, 2024 | markets.businessinsider.comIkena Oncology’s Promising Drug Pipeline Merits a Buy RatingMarch 12, 2024 | benzinga.comIkena Oncology: Q4 Earnings InsightsMarch 12, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for Ikena Oncology (NASDAQ:IKNA)Wedbush reaffirmed an "outperform" rating and set a $8.00 target price on shares of Ikena Oncology in a research report on Tuesday.March 12, 2024 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | globenewswire.comIkena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comIkena Oncology to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 21, 2024 | finance.yahoo.comIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerFebruary 21, 2024 | globenewswire.comIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comDown -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a TurnaroundJanuary 24, 2024 | finance.yahoo.comDown -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a TurnaroundJanuary 22, 2024 | investing.comIkena Oncology Inc (IKNA)January 20, 2024 | benzinga.comIkena Oncology Stock (NASDAQ:IKNA) Dividends: History, Yield and DatesJanuary 19, 2024 | markets.businessinsider.comIkena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational ChangesJanuary 19, 2024 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Outlines Key Priorities and Provides Corporate UpdatesJanuary 18, 2024 | msn.comIkena to cut 35% of workforce, extend cash runway into 2H 2026January 18, 2024 | finance.yahoo.comIkena Oncology Outlines Key Priorities and Provides Corporate UpdatesJanuary 18, 2024 | marketbeat.comTrading was temporarily halted for "IKNA" at 04:01 PM with a stated reason of "News pending."November 11, 2023 | benzinga.comIkena Oncology Stock (NASDAQ:IKNA) Earnings Dates and Earning CallsNovember 11, 2023 | morningstar.comIkena Oncology Inc IKNANovember 10, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Adicet Bio (ACET), Biogen (BIIB) and Ikena Oncology (IKNA)November 10, 2023 | finance.yahoo.comBroker Revenue Forecasts For Ikena Oncology, Inc. (NASDAQ:IKNA) Are Surging HigherNovember 9, 2023 | marketwatch.comIkena Oncology Shares Slump to All-Time Low After IK-930 Cancer Drug DataNovember 9, 2023 | marketbeat.comTrading was temporarily halted for "IKNA" at 02:11 PM with a stated reason of "LULD pause."November 9, 2023 | marketbeat.comTrading was temporarily halted for "IKNA" at 02:11 PM with a stated reason of "LULD pause."November 9, 2023 | msn.comIkena tumbles after early data for lead asset, Q3 financialsNovember 9, 2023 | benzinga.comWhy Is Cancer Firm Ikena Oncology Stock Trading Lower Today?November 9, 2023 | marketbeat.comTrading was temporarily halted for "IKNA" at 09:11 AM with a stated reason of "LULD pause." Trading set to resume at 09:11 AM. November 9, 2023 | marketbeat.comTrading was temporarily halted for "IKNA" at 09:11 AM with a stated reason of "LULD pause."November 9, 2023 | marketbeat.comTrading was temporarily halted for "IKNA" at 09:11 AM with a stated reason of "LULD pause."November 9, 2023 | finance.yahoo.comIkena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comIkena Oncology to Present at Multiple November 2023 Investor ConferencesSeptember 22, 2023 | nasdaq.comWedbush Initiates Coverage of Ikena Oncology (IKNA) with Outperform RecommendationSeptember 22, 2023 | seekingalpha.comIkena Oncology a new buy at Wedbush on cancer asset with new target Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Gates is all about this tiny $2 stock (Ad)What does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthless $2 stock… >>Click here to discover why Bill Gates is all about this tiny $2 stock. IKNA Media Mentions By Week IKNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKNA News Sentiment▼1.070.43▲Average Medical News Sentiment IKNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKNA Articles This Week▼151▲IKNA Articles Average Week Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TSBX News Today CDTX News Today TARA News Today GNTA News Today AVRO News Today LENZ News Today ENTX News Today ATRA News Today CVM News Today ALGS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IKNA) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Crypto for AIWeiss RatingsWarren Buffett's "mystery stock"Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
